Liver Enzyme-Mediated Oxidation of Echinacea purpurea Alkylamides: Production of Novel Metabolites and Changes in Immunomodulatory Activity

Abstract

The medicinal plant Echinacea is widely used to treat upper respiratory infections and is reported to stimulate the human immune system. A major constituent class of Echinacea, the alkylamides, has immunomodulatory effects. Recent studies show that alkylamides are oxidized by cytochrome P450 enzymes, but the immunomodulatory activity of these products is unknown. The objectives of this study were to characterize the products formed by incubation of an Echinacea extract and an isolated alkylamide with human liver microsomes, and to evaluate the influence of Echinacea alkylamides and metabolites on cytokine production by Jurkat human T cells. A novel class of carboxylic acid alkylamide metabolites was identified and shown to be the major constituents present after 2-h incubation of alkylamides with human liver microsomes. Echinacea alkylamides suppressed IL-2 secretion by stimulated T cells, and this effect was significantly lessened upon oxidation of the alkylamides to carboxylic acids and hydroxylated metabolites. These findings highlight the importance of considering the influence of liver enzyme metabolism when evaluating the immunomodulatory effects of alkylamides.

Key words

Echinacea purpurea - Asteraceae - alkylamides - alkamides - cytochrome P450 - metabolism - T-lymphocytes - interleukin-2 (IL-2)

References

• 1 Blumenthal M. Herb sales down 7.4 percent in mainstream market.  Herbalgram. 2005;  66 63
• 2 Barrett B, Vohmann M, Calabrese C. Echinacea for upper respiratory infection.  J Fam Pract. 1999;  48 628-35
• 3 Bauer R. Echinacea: Biological effects and active principles. In: Lawson LD, Bauer R, editors Phytomedicines of Europe. Washington DC; American Chemical Society 1998: p 140-57
• 4 Melchart D, Linde K, Worku F, Sarkady L, Holzmann M, Jurcic K. et al . Results of five randomized studies on the immunomodulatory activity of preparations of Echinacea .  J Altern Complement Med. 1995;  1 145-60
• 5 Turner R B, Bauer R, Woelkart K, Hulsey T C, Gangemi J D. An evaluation of Echinacea angustifolia in an experimental rhinovirus infection.  N Engl J Med. 2005;  353 341-8
• 6 Gertsch J, Schoop R, Kuenzle U, Suter A. Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways.  FEBS Lett. 2004;  577 563-9
• 7 Chen Y, Fu T, Tao T, Yang J, Chang Y, Wang M. et al . Macrophage activating effects of new alkamides from the roots of Echinacea species.  J Nat Prod. 2005;  68 649-52
• 8 Raduner S, Majewska A, Chen J -Z, Xie X -Q, Hamon J, Faller B. et al . Alkylamides from Echinacea are a new class of cannabinomimetics.  J Biol Chem. 2006;  281 14 192-206
• 9 Goel V, Chang C, Slama J V, Barton R, Bauer R, Gahler R. et al . Alkylamides of Echinacea purpurea stimulate alveolar macrophage function in normal rats.  Int Immunopharmacol. 2002;  2 381-7
• 10 Sasagawa M, Cech N B, Gray D E, Elmer G W, Wenner C A. Echinacea alkylamides inhibit Interleukin-2 production by Jurkat human T cells.  Int Immunopharmacol. 2006;  6/7 1214-21
• 11 Matthias A, Gillam E M, Penman K G, Matovic N J, Bone K M, Voss J JD. et al . Cytochrome P450 enzyme-mediated degradation of Echinacea alkylamides in human liver microsomes.  Chem Biol Interact. 2005;  155 62-70
• 12 Coker P S, Camper N D. Bioassays of Echinacea extracts and commercial products. In: Miller SC, He-Ci, Y, editors Echinacea: the genus Echinacea. New York; CRC Press 2004: p 181-99
• 13 Cech N B, Eleazer M S, Shoffner L T, Davis A C, Crosswhite M R, Mortenson A M. High performance liquid chromatography/electrospray ionization mass spectrometry for simultaneous analysis of alkylamides and caffeic acid derivatives from Echinacea purpurea extracts.  J Chromatogr A. 2006;  1103 219-28
• 14 Matthias A, Addison R S, Penman K G, Dickinson R G, Bone K M, Lehmann R P. Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion.  Life Sci. 2005;  77 2018-29
• 15 He X -G, Lin L -Z, Bernart M M, Lian L -Z. Analysis of alkylamides in roots and achenes of Echinacea purpurea by liquid chromatography-electrospray mass spectrometry.  J Chromatogr A. 1998;  815 205-11
• 16 Woelkart K, Xu W, Pei Y, Makriyannis A, Picone R, Bauer R. The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots.  Planta Med. 2005;  71 701-5
• 17 Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D. et al . Cannabinoid-receptor expression in human leukocytes.  Eur J Biochem. 1993;  214 173-80
• 18 Kaplan B LF, Ouyang Y, Herring A, Yea S S, Razdan R, Kaminski N E. Inhibition of leukocyte function and interleukin-2 gene expression by 2-methylarachidonyl-(2′-fluoroethyl)amide, a stable congener of the endogenous cannabinoid receptor ligand anandamide.  Toxicol Appl Pharmacol. 2005;  205 107-15
• 19 Raitio K H, Salo O MH, Nevalainen T, Poso A, Jaervinen T. Targeting the cannabinoid CB2 receptor: Mutations, modeling and development of CB2 selective ligands.  Current Med Chem. 2005;  12 1217-37
• 20 Woelkart K, Koidl C, Grisold A, Gangemi J D, Turner R B, Marth E. et al . Bioavailability and pharmacokinetics of alkamides from the roots of Echinacea angustifolia in humans.  J Clin Pharmacol. 2005;  45 683-9